CONIVAPTAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C32H26N4O2
Molecular Weight	498.5744
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC2=C(N1)C3=C(C=CC=C3)N(CC2)C(=O)C4=CC=C(NC(=O)C5=C(C=CC=C5)C6=CC=CC=C6)C=C4

InChI

InChIKey=IKENVDNFQMCRTR-UHFFFAOYSA-N

InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)

HIDE SMILES / InChI

Molecular Formula	C32H26N4O2
Molecular Weight	498.5744
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/ppa/conivaptan.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21409494 | https://www.ncbi.nlm.nih.gov/pubmed/18926434

Conivaptan is an arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V1A and V2. The antidiuretic action of AVP is mediated through activation of the V2 receptor, which functions to regulate water and electrolyte balance at the level of the collecting ducts in the kidney. Conivaptan was approved in 2004 for hyponatremia caused by syndrome of inappropriate antidiuretic hormone. Conicaptan is being evaluated for reduce intracranial pressure in patients with traumatic brain injury, and as a treatment for heart failure.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vasopressin V1a receptor 16 Target ID: CHEMBL1889 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	Antagonist 2760		0.43 nM [Ki]
Vasopressin V2 receptor 15 Target ID: CHEMBL1790 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	Antagonist 2760		0.36 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Hyponatremia 4 Sources: https://www.drugs.com/ppa/conivaptan.html	Primary	Approved 8360	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Approved Use VAPRISOL is a vasopressin receptor antagonist indicated to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia. Launch Date 1.13581438E12
Traumatic brain injury 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21409494	Palliative	Phase I 424	Unknown Approved Use Unknown
Liver cirrhosis 15 Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	Palliative	Phase II 1144	Unknown Approved Use Unknown
Heart failure 87 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18926434	Palliative	Phase III 663	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
2681 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10638391	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
619 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	40 mg/kg single, intravenous dose: 40 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4813 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10638391	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10638391	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	40 mg/kg single, intravenous dose: 40 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	40 mg/kg single, intravenous dose: 40 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16522696	unhealthy, 68.7 years (range: 35–90 years) n = 27 Health Status: unhealthy Condition: euvolemic hyponatremia \| hypervolemic hyponatremia Age Group: 68.7 years (range: 35–90 years) Sex: M+F Population Size: 27 Sources: https://pubmed.ncbi.nlm.nih.gov/16522696	Sources: https://pubmed.ncbi.nlm.nih.gov/16522696
120 mg 1 times / day multiple, intravenous Highest studied dose Dose: 120 mg, 1 times / day Route: intravenous Route: multiple Dose: 120 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021697lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Congestive heart failure Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021697lbl.pdf	Other AEs: Hypotension, Thirst... Other AEs: Hypotension Thirst Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021697lbl.pdf
40 mg 1 times / day multiple, intravenous Recommended Dose: 40 mg, 1 times / day Route: intravenous Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_MEDR.pdf Page: p. 64	unhealthy, adult n = 445 Health Status: unhealthy Age Group: adult Population Size: 445 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_MEDR.pdf Page: p. 64	Disc. AE: Hypopituitarism, Infusion site reaction... AEs leading to discontinuation/dose reduction: Hypopituitarism (0.2%) Infusion site reaction (0.2%) Infusion site phlebitis (1.6%) Infusion related reaction (0.2%) Sepsis NOS (0.2%) Pneumonia NOS (0.2%) Blood creatinine increased (0.2%) Blood sodium increased (0.2%) Blood urea increased (0.2%) Heart rate increased (0.2%) Hypernatremia (0.8%) Epilepsy NOS (0.2%) Agitation (0.2%) Renal failure acute (0.2%) Respiratory arrest (0.2%) Respiratory failure (0.2%) Cyanosis peripheral (0.2%) Phlebitis NOS (0.2%) Phlebitis superficial (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_MEDR.pdf Page: p. 64
12.5 mg single, intravenous Dose: 12.5 mg Route: intravenous Route: single Dose: 12.5 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	unhealthy n = 6 Health Status: unhealthy Condition: Liver Cirrhosis Population Size: 6 Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	Other AEs: Dizziness... Other AEs: Dizziness (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00592475
20 mg 1 times / day multiple, intravenous Dose: 20 mg, 1 times / day Route: intravenous Route: multiple Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00478192	unhealthy n = 20 Health Status: unhealthy Condition: Euvolemic or Hypervolemic Hyponatremia Population Size: 20 Sources: https://clinicaltrials.gov/ct2/show/NCT00478192	Other AEs: Coagulopathy, Cardiac failure congestive... Other AEs: Coagulopathy (serious, 1 patient) Cardiac failure congestive (serious, 2 patients) Multi-organ failure (serious, 1 patient) Hyponatraemia (serious, 1 patient) Transient ischaemic attack (serious, 1 patient) Renal failure (serious, 1 patient) Respiratory distress (serious, 1 patient) Hypocoagulable state (below serious, 1 patient) Leukocytosis (below serious, 1 patient) Arrhythmia ventricular (below serious, 1 patient) Abdominal discomfort (below serious, 1 patient) Abdominal distension (below serious, 2 patients) Abnormal bowel sounds (below serious, 1 patient) Constipation (below serious, 2 patients) Nausea (below serious, 2 patients) Fatigue (below serious, 1 patient) Hypothermia (below serious, 1 patient) Pain (below serious, 2 patients) Procedural pain (below serious, 1 patient) Breath sounds abnormal (below serious, 1 patient) Chest X-ray abnormal (below serious, 1 patient) Hypoalbuminaemia (below serious, 1 patient) Hypomagnesaemia (below serious, 2 patients) Hypophosphataemia (below serious, 1 patient) Hypovolaemia (below serious, 1 patient) Muscle spasms (below serious, 1 patient) Headache (below serious, 1 patient) Lethargy (below serious, 1 patient) Anxiety (below serious, 1 patient) Dysuria (below serious, 1 patient) Cough (below serious, 1 patient) Postnasal drip (below serious, 1 patient) Rales (below serious, 1 patient) Pruritus (below serious, 1 patient) Hypotension (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00478192
20 mg 2 times / day multiple, intravenous Dose: 20 mg, 2 times / day Route: intravenous Route: multiple Dose: 20 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00478192	unhealthy n = 20 Health Status: unhealthy Condition: Euvolemic or Hypervolemic Hyponatremia Population Size: 20 Sources: https://clinicaltrials.gov/ct2/show/NCT00478192	Other AEs: Cardiac failure congestive, Pneumonia... Other AEs: Cardiac failure congestive (serious, 1 patient) Pneumonia (serious, 1 patient) Respiratory acidosis (serious, 1 patient) Coronary artery bypass (serious, 1 patient) Hypotension (serious, 1 patient) Dry eye (below serious, 1 patient) Constipation (below serious, 2 patients) Nausea (below serious, 1 patient) Vomiting (below serious, 2 patients) Chest pain (below serious, 1 patient) Fatigue (below serious, 1 patient) Oedema peripheral (below serious, 1 patient) Bronchitis chronic (below serious, 1 patient) Contusion (below serious, 1 patient) Blood pressure decreased (below serious, 1 patient) Cardiac murmur (below serious, 1 patient) Carotid bruit (below serious, 1 patient) Heart sounds abnormal (below serious, 1 patient) Dehydration (below serious, 1 patient) Hypernatraemia (below serious, 1 patient) Hypokalaemia (below serious, 1 patient) Neck pain (below serious, 1 patient) Headache (below serious, 1 patient) Insomnia (below serious, 2 patients) Psychotic disorder (below serious, 1 patient) Haematuria (below serious, 1 patient) Pruritus (below serious, 1 patient) Haematoma (below serious, 1 patient) Thrombophlebitis (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00478192
22.5 mg single, intravenous Dose: 22.5 mg Route: intravenous Route: single Dose: 22.5 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	unhealthy n = 9 Health Status: unhealthy Condition: Liver Cirrhosis Population Size: 9 Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	Other AEs: Atrial tachycardia, Urinary tract infection... Other AEs: Atrial tachycardia (serious, 1 patient) Urinary tract infection (serious, 1 patient) Encephalopathy hepatic (serious, 1 patient) Atrial flutter (below serious, 1 patient) Nausea (below serious, 1 patient) Vomiting (below serious, 1 patient) Polydipsia (below serious, 1 patient) Back pain (below serious, 1 patient) Productive cough (below serious, 1 patient) Dry skin (below serious, 1 patient) Phlebitis (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00592475
60 mg single, intravenous Dose: 60 mg Route: intravenous Route: single Dose: 60 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00843986	unhealthy n = 6 Health Status: unhealthy Condition: Acute Decompensated Heart Failure Population Size: 6 Sources: https://clinicaltrials.gov/ct2/show/NCT00843986	Other AEs: Cardiac arrest, Atrial flutter... Other AEs: Cardiac arrest (serious, 1 patient) Atrial flutter (below serious, 1 patient) Ventricular tachycardia (below serious, 1 patient) Constipation (below serious, 1 patient) Infusion site erythema (below serious, 3 patients) Infusion site pain (below serious, 1 patient) Pyrexia (below serious, 1 patient) Heart rate increased (below serious, 1 patient) Muscle spasms (below serious, 1 patient) Pain in extremity (below serious, 1 patient) Headache (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00843986

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579	inhibitor 1752	inhibitor 1837	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1437 CYP1A2 1509 CYP2C19 1463	P-gp 1527

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 20, 48	strong [IC50 0.47 uM]	yes (co-administration study) Comment: coadministration with midazolam or simvastatin significantly increased both CYP3A4 substrates Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 20, 48
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 48.0	weak [IC50 198.3 uM]
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 48.0	yes [IC50 12.6 uM]
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021697s005lbl.pdf Page: 10, 48	yes [IC50 13.3 uM]	yes (co-administration study) Comment: coadministration with warfarin increased warfarin WUC by 14% amd Cmax by 17% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021697s005lbl.pdf Page: 10, 48
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 48.0	yes [IC50 19.2 uM]
P-gp 1626	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021697s005lbl.pdf Page: 10, 21	yes	yes (co-administration study) Comment: coadministration with digoxin resulted in increased Cmax by 79% and AUC by 43% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021697s005lbl.pdf Page: 10, 21

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1527	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 21, 48	yes
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 38.0	yes		yes (co-administration study) Comment: ketoconazole increased conivaptan AUC 11-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 38.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_PHARMR.pdf Page: 20, 25

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:681850	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:681850
ChemicalBook	CB51011161	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51011161
MolPort	MolPort-046-703-477	https://www.molport.com/shop/molecule-link/MolPort-046-703-477
ZINC	ZINC000012503187	http://zinc15.docking.org/substances/ZINC000012503187

PubMed

Title	Date	PubMed

Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide.	2001 May	11343672
Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.	2001 Nov 13	11705818
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.	2002 Apr	12062361
Vasopressin antagonists in CHF: ready for clinical trials?	2002 Apr	12062356
Conivaptan (Yamanouchi).	2002 Jan	12054079
Gateways to clinical trials.	2003 Nov	14685303
Conivaptan: YM 087.	2004	15293869
Vasopressin antagonists in heart failure.	2004 Dec	16036044
Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.	2004 Feb	14975041
Gateways to clinical trials.	2004 Jul-Aug	15349141
Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.	2005 Jan 10	15659304
Gateways to clinical trials.	2005 Jan-Feb	15834459
Conivaptan Yamanouchi.	2005 Mar	15816509
Vasopressin antagonism: a future treatment option in heart failure.	2005 Mar	15695526
Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.	2005 Mar	15661579
Vasopressin receptor antagonists in the management of acute heart failure.	2005 May	15926866
Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.	2005 May 2	15847853
New drugs for prevention, relief. How you might benefit if 3 medications win FDA approval.	2005 Oct	16294398
Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.	2006 Jan	16375624
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.	2006 Jan	16319185
Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.	2006 Jun	16522696
Vasopressin antagonists--progress and promise.	2006 Nov 16	17105758
Cerebral correlates of hyponatremia.	2007	17356196
[Vasopressin antagonists in treatment of hyponatremia].	2007 Aug	18018383
Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].	2007 Fall	17919259
Recognition and treatment of hyponatremia in acutely ill hospitalized patients.	2007 Feb	17472815
A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).	2007 Jan	17202666
Hyponatremia and vasopressin antagonism in congestive heart failure.	2007 Nov	17847041
Gateways to clinical trials.	2007 Sep	17982511
Conivaptan: a step forward in the treatment of hyponatremia?	2008 Apr	18728836
Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.	2008 Aug	18437428
Conivaptan: potential therapeutic implications in heart failure.	2008 Jun	18537764
Non-peptide arginine-vasopressin antagonists: the vaptans.	2008 May 10	18468546
Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.	2009 Jan	19057376
Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis.	2009 Jul	19542534
AVP receptor antagonists in patients with CHF.	2009 Jun	18766439
Pharmacology of vasopressin antagonists.	2009 Jun	18766438

Patents

Sample Use Guides

In Vivo Use Guide

IV: 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2 to 4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium not rising sufficiently; total duration of therapy not to exceed 4 days. Note: If patient requires 40 mg/24 hours, may administer two consecutive 20 mg/100 mL premixed solutions over 24 hours (ie, 20 mg over 12 hours followed by 20 mg over 12 hours).

Route of Administration: Intravenous

In Vitro Use Guide

Binding of conivaptan with recombinant human vasopressin V1a and V2 receptors was studied using [3H]-Arg-vasopressin as a radioligand. Conivaptan binds to V1a with Ki of 0.43 and to V2 receptor with Ki of 0.36 nM.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 21:48:03 UTC 2023` Edited by `admin` on `Thu Jul 06 21:48:03 UTC 2023`
Record UNII	0NJ98Y462X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CONIVAPTAN

Official Name

English

(1,1'-BIPHENYL)-2-CARBOXAMIDE, N-(4-((4,5-DIHYDRO-2-METHYLIMIDAZO(4,5-D)(1)BENZAZEPIN-6(1H)-YL)CARBONYL)PHENYL)-

Systematic Name

English

4''-((4,5-DIHYDRO-2-METHYLIMIDAZO(4,5-D)(1)BENZAZEPIN-6(1H)-YL)CARBONYL)-2-BIPHENYLCARBOXANILIDE

Common Name

English

CONIVAPTAN [VANDF]

Common Name

English

conivaptan [INN]

Common Name

English

CONIVAPTAN [MI]

Common Name

English

Conivaptan [WHO-DD]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000009945